Close
CDMO Safety Testing 2026
Novotech

Medtech Company IME Technologies Moves to New and Much Larger R & D And Production Facility in Waalre, The Netherlands

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.
- Advertisement -

Medical technology company IME Technologies, developer, producer and scientific partner in the field of biomedical electro spinning processes and equipment, has moved its operations from Geldrop to a significantly larger facility in Waalre with effect from 26 March.

IME’s state-of-the-art technology enables scientists to develop medical implants that help the human body to repair itself, such as heart valves, blood vessels, nerves, tendons, skin and bone. IME is a world leader in this field. Later this year (September 2018) IME Technologies will officially open the new facility during an event themed ‘The future of regenerative medicine’.

In the new IME building at the Van Dijklaan in Waalre, the company will have the ability to, according to the highest standards, not only produce its electro spinning machines autonomously, but also the actual extracellular matrices or scaffolds for the intended medical implants. These are developed by IME in close collaboration with various partners. The company has a growing number of customers and partners worldwide in industry, science and medical institutes.

IME’s technological solutions are able to mimic the natural human extracellular matrix for implants in the human body in nanometer format, applying specific polymers. Human cells attach to this matrix leading to new body tissue. This is in contrast to implants of traditional structures, which are seen as foreign and therefore can be rejected or lead to scar tissue.

About IME Technologies
IME Technologies develops and implements electro spin processes and equipment for the manufacturing of medical devices for (regenerative) medicine. Electro spinning is a flexible process for producing extremely thin fibres and structures that have excellent properties for use in regenerating human tissue. IME Technologies has developed unique electro spin technology for the reproducible and scalable production of electro spun material under medical conditions. Customers include industry, scientists and institutions.

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.

AbbVie to Invest $1.4B in North Carolina Manufacturing Plant

AbbVie has outlined plans to build a major new...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป